A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
Latest Information Update: 12 May 2025
At a glance
- Drugs SGMIB anti-HER2 monoclonal antibody I-131 (Primary)
- Indications Advanced breast cancer; Brain metastases; Gastric cancer; Male breast cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Precirix
Most Recent Events
- 10 Jun 2024 According to a PRECIRIX media release, data from this trial will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 annual meeting, 8-11 June in Toronto, ON.
- 13 May 2024 Status changed from active, no longer recruiting to discontinued.
- 12 Jan 2024 Planned End Date changed from 17 Jan 2025 to 31 Jan 2024.